|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Darwich, Abbass; Silvestri, Alessandra; Benmebarek, Mohamed-Reda; Mouries, Juliette; Cadilha, Bruno; Melacarne, Alessia; Morelli, Lapo; Supino, Domenico; Taleb, Alexandre; Obeck, Hannah; Sustmann, Claudio; Losurdo, Agnese; Masci, Giovanna; Curigliano, Giuseppe; Kobold, Sebastian; Penna, Giuseppe und Rescigno, Maria
(2021):
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1.
In: Journal for Immunotherapy of Cancer, Bd. 9, Nr. 11, e003224
Karches, Clara H.; Benmebarek, Mohamed-Reda; Schmidbauer, Moritz L.; Kurzay, Mathias; Klaus, Richard; Geiger, Martina; Rataj, Felicitas; Cadilha, Bruno L.; Lesch, Stefanie; Heise, Constanze; Murr, Ramona; vom Berg, Johannes; Jastroch, Martin; Lamp, Daniel; Ding, Jian; Duewell, Peter; Niederfellner, Gerhard; Sustmann, Claudio; Endres, Stefan; Klein, Christian und Kobold, Sebastian
(2019):
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
In: Clinical Cancer Research, Bd. 25, Nr. 19: S. 5890-5900
Sustmann, Claudio; Dickopf, Steffen; Regula, Jörg T.; Kettenberger, Hubert; Molhoj, Michael; Gassner, Christian; Weininger, Diana; Fenn, Sebastian; Manigold, Tobias; Kling, Lothar; Kuenkele, Klaus-Peter; Schwaiger, Manfred; Bossenmaier, Birgit; Griese, Julia J.; Hopfner, Karl-Peter; Graff-Meyer, Alexandra; Stahlberg, Henning; Ringler, Philippe; Lauer, Matthias E.; Brinkmann, Ulrich; Schäfer, Wolfgang und Klein, Christian
(2019):
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
In: Mabs, Bd. 11, Nr. 8: S. 1402-1414
Castoldi, Raffaella; Schanzer, Jürgen; Panke, Christian; Jucknischke, Ute; Neubert, Natalie J.; Croasdale, Rebecca; Scheuer, Werner; Auer, Johannes; Klein, Christian; Niederfellner, Gerhard; Kobold, Sebastian und Sustmann, Claudio
(2016):
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
In: Protein Engineering Design & Selection, Bd. 29, Nr. 10: S. 467-475